Chris Viehbacher, Biogen CEO (Photographer: Scott Eells/Bloomberg via Getty Images)
Chris Viehbacher once again sets out to revamp R&D at a major biopharma. The last try led to his ouster
An outspoken Chris Viehbacher spent six years trying unsuccessfully to prod Sanofi’s multibillion-dollar R&D group into a more productive phase that relied less on partners …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.
